Polyethylene Glycol Losenatide Injection is used in adults to improve glycemic control in patients with type 2 diabetes mellitus. It is a long-acting GLP-1 receptor agonist that promotes glucose-dependent insulin secretion, and is used in conjunction with dietary control and exercise, alone or in combination with metformin, to improve glycemic control in patients with type 2 diabetes mellitus, when used in accordance with medical advice. Adverse reactions include nausea, vomiting, diarrhea, hypoglycemia, bleeding at the injection site, etc. It is contraindicated in patients with medullary carcinoma of the thyroid, family history of medullary carcinoma of the thyroid, or patients with multiple endocrine neoplasia syndrome type 2, patients with type 1 diabetes mellitus, and patients with diabetic ketoacidosis. It is not recommended for pregnant and lactating women and patients under 18 years of age. Use should start with a small dose and monitor blood glucose at the same time. If diagnosed with diabetes, it is recommended to consult a regular hospital, complete the relevant examinations, have the doctor formulate a treatment plan and follow the doctor’s instructions for standardized treatment. The drug should be applied under the guidance of a doctor.